To compare performance characteristics of dedicated dualhead gamma imaging and mammography in screening women with mammographically dense breasts.
BREAST IMAGING: Adding Gamma Imaging to Screening Mammography in Dense Breasts
Rhodes et al ( 17 ) . The development of gamma cameras uniquely confi gured for breast imaging has yielded improved detection of small tumors ( 18, 19 ) . While studies (20) (21) (22) (23) (24) (25) (26) (27) (28) evaluating gamma technology for breast imaging have primarily focused on diagnostic applications, investigators in two studies in small numbers of patients ( 29, 30 ) have suggested a promising role in breast cancer screening. We reported the sensitivity of a dedicated dual-head gamma camera system to be greater than 90% for the detection of small breast tumors ( 25 ) . Researchers ( 20, 21, 27, 31 ) who have studied a number of other dedicated nuclear medicine-based techniques, including positron emission mammography, breast specifi c gamma imaging, and various other dedicated technologies under investigation, also reported high sensitivities for detection of small breast tumors. In our work to date, we have referred to the use of dedicated cadmium zinc telluride (CZT)-based detectors in a dualhead confi guration as molecular breast imaging to distinguish this functional imaging method from anatomically based techniques, such as mammography. It early detection of these cancers by other methods may have a survival benefi t.
The combination of whole-breast screening ultrasonography (US) and mammography in women with dense breasts and elevated risk of breast cancer yielded a sensitivity of 77.5% versus 50% for either modality alone ( 13 ). However, the addition of US substantially increased false-positive fi ndings, and the positive predictive value (PPV) of biopsy recommendation after US was less than 10%. Breast magnetic resonance (MR) imaging is superior to US and mammography in terms of sensitivity, but the relatively low specifi city, complexity of interpretation, contraindications (eg, claustrophobia and implanted devices), and high cost are substantial disadvantages ( 14, 15 ) . To our knowledge, there have been no comparative trials of mammography and MR imaging limited to women with dense breasts and there is currently insufficient evidence for supplemental screening with MR imaging for this indication alone ( 16 ) . The limitations of these modalities underscore the need for a screening method with both high sensitivity and reasonable cost for women with mammographically dense breasts.
Mammographic detection of breast cancer depends on the visual distinction of normal breast structures from tumor, a distinction that may be obscured by surrounding dense parenchyma. In contrast, nuclear medicine techniques exploit functional differences between tumor and normal cells that result in different levels of radiotracer uptake and are independent of the surrounding parenchymal density A cross nine randomized trials, screening mammography has been shown to reduce mortality from breast cancer by 15%-32% ( 1 ) . Absolute mortality reduction correlates with the magnitude of reduction in cancers that have spread to axillary lymph nodes at the time of diagnosis ( 2 ) . Methods that depict node-negative cancers not detected with mammography should further improve mortality reduction, though this capability has not yet been shown.
The sensitivity of mammography is reduced in dense breasts (ie, those described as heterogeneously dense or extremely dense) ( 3 ) . Estimates of mammographic sensitivity in women with extremely dense breasts range from 30% to 63% (4) (5) (6) (7) (8) (9) (10) (11) . The diagnosis of cancer during the interval between screening examinations is increasingly likely in women with dense breast tissue (odds ratio, 17.8 for interval cancer among women with Ն 75% breast density compared with women with , 10% breast density; 95% confi dence interval [CI]: 4.8, 65.9) ( 12 ). Interval cancers are associated with a worse prognosis relative to screening-detected cancers. It is likely that a proportion of interval cancers are mammographically occult but present at the time of the last screening, and
Implications for Patient Care
Findings in this proof-of-principle n study demonstrate the effectiveness of dedicated dual-head gamma imaging as a supplemental screening tool in women with mammographically dense breasts.
To be of clinical importance for n screening, dedicated dual-head gamma imaging will need to show equivalent performance at decreased radiation doses.
Advances in Knowledge
Addition of dedicated dual-head n gamma imaging with 99m Tcsestamibi to screening mammography increased the absolute sensitivity for breast cancer detection from 27% with mammography alone to 91% with the combination of imaging tests ( P = .016).
The number of patients with n breast cancer per number of screening examinations with abnormal fi ndings (PPV 1 ) was 3% for mammography and 12% for gamma imaging ( P = .01).
Addition of gamma imaging to n mammography signifi cantly increased the detection of nodenegative breast cancer in dense breasts by 7.5 per 1000 women screened (95% confi dence interval: 3.6, 15.4). 
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Two-view mammography was performed by Mammography Quality Standards Act-certifi ed technologists by using either screen-fi lm (Lorad M-IV; Hologic, Bedford, Mass) or digital (Selenia; Hologic) mammography. Mayo Clinic was in the process of transitioning from screen-fi lm mammography units to digital mammography units during the course of this study. At the start of the study in 2005, most participants underwent screen-fi lm mammography. By April 2008, all participants underwent digital mammography. The determination of whether patients underwent screen-fi lm or digital mammography was entirely independent of their participation in this study.
Women were enrolled prior to un dergoing screen-film or digital head systems ( Fig 1 ) that were mounted on a modifi ed mammographic gantry. Each system comprised two opposing 20 3 20-cm CZT-based detectors (Prototype CZT, GE Medical Systems, Haifa, Israel; LumaGem, Gamma Medica-Ideas, Northridge, Calif) that were previously described ( 25, 34 ) . Patients received a single intravenous injection of 740 MBq (20 mCi) of the radiopharmaceutical technetium Tc 99m ( 99m Tc) sestamibi (Cardiolite; DuPont Merck, Wilmington, Del), and imaging commenced 5 minutes after injection. Each breast was imaged in both craniocaudal and mediolateral oblique positions for 10 minutes per view by using light compression to limit patient motion. Nuclear medicine technologists were trained in breast positioning.
is also important to differentiate this semiconductor-based technology from the scintillating crystal detector of commercially available breast-specifi c gamma imaging units. CZT detector technology offers substantial advantages over the traditional scintillating detectors in terms of intrinsic spatial and energy resolution. The CZT-based dual-head dedicated gamma camera technology is now commercially available, and administration of the radiotracer is Food and Drug Administration approved.
The purpose of this study was to prospectively and independently compare performance characteristics of dedicated dual-head gamma imaging and mammography in screening women with mammographically dense breasts.
Materials and Methods

Study Population
Women with heterogeneously or extremely dense breasts, characterized as such on the basis of fi ndings on the most recent prior mammogram, who were 25 years old and older and were undergoing routine screening mammography were enrolled in an institutional review board-approved, Health Insurance Portability and Accountability Actcompliant protocol. We also allowed women younger than 50 years who had not undergone prior mammography to enroll, as most of such women have dense breasts ( 32, 33 ) . To increase the likelihood of cancer in the study population and power the study to detect signifi cant differences in diagnostic performance, we required subjects to have at least one of the risk factors listed in Table 1 . Pregnant and lactating women were excluded. Women who had undergone breast surgery in the prior 12 months or needle biopsy in the prior 3 months were excluded, as were those taking tamoxifen citrate (Nolvadex; AstraZeneca, Wilmington, Del), raloxifene (Evista; Eli Lilly, Indianapolis, Ind), or an aromatase inhibitor.
Imaging Procedures and Interpretation
At least two-view gamma imaging was performed by using one of two dual- Note.-Unless otherwise specifi ed, data are numbers of patients. Numbers in parentheses are percentages, and percentages were rounded.
* The analysis set includes participants in whom both initial screening mammographic and gamma imaging studies were completed and cancer status was verifi ed. † Numbers in parentheses are ranges. ‡ Eligibility was determined by density assessed on a previous mammogram prior to study entry; mammographic density reported in this table refers to density assessed from the study mammogram. § Although participants may have qualifi ed for multiple risk factor categories, they were assigned to only one risk factor category in this table. These risk factors are listed in order of priority. The last two risk factors with respect to fi rst-and second-degree relatives with a history of breast cancer refer to subjects who qualifi ed on the basis of family history but did not meet the Gail or Claus model risk threshold levels.
|| Chest, mediastinal, or axillary irradiation was received prior to age 30 years and at least 8 years prior to study enrollment.
# A total of fi ve women younger than 50 years old with no prior mammogram were enrolled, and all had heterogeneously dense breasts on the mammogram obtained at the time of the study.
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Rhodes et al ductal carcinoma in situ (DCIS) within 365 days of initial study mammographic imaging. Similar to other breast imaging trials, a negative cancer status verifi cation was targeted for 365 days as determined with negative or benign fi ndings at imaging at least 330 days after initial study mammography, with benign histopathologic fi ndings, or with medical record review or patient interview confi rming no breast cancer diagnosis ( 10,13 ). The fi nal histopathologic fi ndings in each lesion were determined from the most severe of surgical excision or core needle biopsy results. All malignancies and atypical lesions were excised. Lesions that were detected by using gamma imaging but not by using other modalities, and therefore those for which a patient did not undergo biopsy, were classifi ed as false-positive results if further diagnostic imaging and/or clinical fi ndings at 365-day follow-up revealed no cancer.
Statistical Analysis
Diagnostic yield (ie, the proportion of women with positive results of a screening test and positive results with the reference standard), sensitivity, specifi city, recall rate, and positive predictive values (PPVs) were calculated in patients with verifi ed cancer status. Recall rate was defi ned as the percentage of patients recalled for follow-up studies initiated because of abnormal fi ndings with mammography or gamma mammographic interpretation and all other ancillary clinical information. Images were examined for the presence of abnormal tracer uptake and assigned a score by using an uptake score on a scale of 1-5, as follows: score 1, no abnormal uptake; score 2, benign, normal physiologic uptake; score 3, indeterminate uptake; score 4, uptake suspicious for malignancy; and score 5, uptake highly suspicious for malignancy. Uptake scores of 3, 4, or 5 were considered to indicate a test with positive results, and scores of 1 or 2 were considered to indicate a test with negative results. This fi ve-point uptake scale differed from BI-RADS categories in that a mammogram with an assessment of BI-RADS category of 3 was considered to be negative because it does not lead to immediate diagnostic evaluation, whereas a gamma image with an uptake score of 3 (indeterminate uptake) was defi ned a priori as positive because it triggered a combination read of gamma images and mammograms, which in turn was used to guide additional diagnostic evaluation. A combination read was performed only for gamma imaging studies with uptake scores of 3-5. Figure 2 provides the algorithm that was used for diagnostic evaluation in patients with positive gamma images.
Determination of Reference Standard
Cancer status was verifi ed as disease positive on the basis of any histopathologic diagnosis of invasive breast cancer or All screening mammograms were performed and interpreted at Mayo Clinic (Rochester, Minn) by dedicated breast radiologists in the course of routine clinical practice. Radiologists who interpreted the screening mammograms were blinded to study participation and gamma imaging results, had standard access to relevant clinical information and prior mammograms, and used standard Breast Imaging Reporting and Data System (BI-RADS) terminology ( 3 ). BI-RADS assessments and linked recommendations for mammography were as follows: category 1, negative results, rou tine screening; category 2, benign, routine screening; category 3, probably benign, 6-month follow-up; category 4, suspicious, consider biopsy; category 5, highly suggestive of malignancy, take appropriate action; and category 0, incomplete, additional imaging recommended (diagnostic mammography, US and/or MR imaging). An assessment of category 0, 4, or 5 was considered to indicate a test with positive results. Percentage of density on the current mammogram was visually assessed as fatty replaced ( , 25%), scattered fi broglandular densities (25%-50%), heterogeneously dense (51%-75%), or extremely dense ( . 75%).
Review of gamma images was performed by either of two Mayo Clinic dedicated breast radiologists (S.W.P. and D.H.W., with experience in interpreting images in more than 100 studies) who were blinded to the screening 
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Results
Of 1007 women enrolled between September 2005 and February 2009, 969 completed imaging and met eligibility criteria ( Fig 3 ) ; of 969 eligible participants, 33 (3%) were excluded because of lack of the reference standard. The fi nal analysis set comprised 936 participants with verifi ed cancer status: Cancer status was verifi ed by using negative or benign fi ndings on a subsequent annual mammogram in 898 (96%), positive pathologic fi ndings in 11 (1%), negative pathologic fi ndings in prophylactic mastectomy specimens in fi ve (0%), negative pathologic fi ndings at core biopsy in three (0%), patient interview in 15 (2%), and negative clinical examination fi ndings in four (0%). Of the 898 patients with cancer status verifi ed by using fi ndings on a subsequent annual mammogram, 23 (3%) returned earlier than the 365-day target, six (1%) returned between 330 and 344 days, and 17 (2%) returned between 345 and 364 days after gamma imaging. Of 936 women, 802 (86%) had heterogeneously dense or extremely dense breasts on a study mammogram; because study entry was based on the density on the prior rather than on the current mammogram, women whose current mammogram was not considered to show dense breasts were included. Table 2 summarizes the main outcome measures of diagnostic yield, sensitivity, specifi city, recall rate, and PPV for mammography and dedicated dualhead gamma imaging.
Of 936 participants, 11 had cancer: In one patient, cancer was detected only with mammography; in seven patients, cancer was detected only with gamma imaging; in two patients, cancer was detected with both modalities; and in one patient, cancer was not detected with either modality ( Tables 3, 4 ) . Diagnostic yield was 3.2 per 1000 (95% CI: 1.1, 9.4) for mammography and 9.6 per 1000 (95% CI: 5.1, 18.2) for gamma imaging ( P = .07, mammography vs gamma imaging). Diagnostic yield was were used for reader variability analysis. Of the images from 96 studies, 49 were originally interpreted by one author (S.W.P.) and 47 were originally interpreted by another author (D.H.W.). Both radiologists were blinded for the interpretation of images from the entire subset of 96 studies after a period greater than 6 months following the original interpretation to allow calculation of interreader and intrareader variability. The Cohen unweighted k statistic was calculated to assess the proportion of interreader and intrareader agreement expected beyond chance, where k of 1 corresponds to perfect agreement and k of 0 indicates agreement expected by chance alone ( 37 ). Landis and Koch ( 38 ) suggested that k values of less than 0.20 indicate slight agreement; 0.21-0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; and 0.81-1.00, almost perfect agreement. The variability analysis was performed by using fi ve distinct uptake score categories of 1-5 that were previously described and by imaging. PPVs were calculated as the ratios of the number of patients with breast cancer per number of screening examinations with abnormal fi ndings (PPV 1 ) and the number of breast cancers diagnosed per number of biopsies performed (PPV 3 ). The McNemar test for correlated proportions was used to assess signifi cance for sensitivity, specifi city, and recall rate. P values for the PPV were calculated by using methods described by Moskowitz and Pepe ( 35 ) . All P values were reported as two sided. P , .05 was set as the threshold value for a signifi cant difference, and CIs were reported at the 95% level. Exact 95% CIs were calculated by using the Wilson method without continuity correction ( 36 ).
Reader Variability
Images from a subset of 96 gamma imaging studies, comprising all studies with breast lesions (11 with breast cancer, three with atypia, 26 with benign lesions) and images from 56 randomly selected studies without breast lesions 
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Rhodes et al 10.7 per 1000 (95% CI: 5.8, 19.6) for mammography and gamma imaging combined ( P = .016), with a supplemental yield of 7.5 per 1000 women screened (95% CI: 3.6, 15.4). One participant had a second ipsilateral cancer that was detected with gamma imaging only.
Ten of 12 cancers were detected with gamma imaging, and three were detected with mammography. Eight cancers were detected with gamma imaging only and not with mammography, as follows: DCIS, two; invasive ductal carcinoma (IDC), three; invasive lobular carcinoma (ILC), two; and tubulolobular carcinoma, one. Axillary lymph nodes were negative for metastatic carcinoma in fi ve of seven patients with invasive cancer and in all patients with invasive cancers detected with gamma imaging and not with mammography. Examples of these cancers are in Figures E1-E3 (online).
The median size of the largest invasive cancer per participant was 11 mm (range, 4-51 mm; mean, 20 mm). The median size of the six invasive cancers detected by using gamma imaging only was 11 mm (range, 4-51 mm; mean, 16 mm). The largest invasive cancer detected by using gamma imaging but not by using mammography was a 51-mm ILC. The cancer that was detected by using mammography only and not by using gamma imaging manifested as microcalcifi cations involving a tumor size less than 5 mm, with a histopathologic fi nding of DCIS. Two cancers were detected by using both modalities: one 13-mm IDC and one 34-mm IDC. One tumor was undetected by using both mammography and gamma imaging: The patient with this tumor had DCIS involving the entire breast, which was interpreted as BI-RADS category 3 (probably benign) with screening digital mammography, US, and MR imaging performed at the time of the gamma imaging study but was later detected at 6-month follow-up diagnostic mammography.
At the participant level, sensitivity of mammography was 27% (three of 11), and sensitivity of dedicated dualhead gamma imaging was 82% (nine of 11), with P = .07. The sensitivity of Table 2 Diagnostic 
Rhodes et al imaging comprised 10 fi broadenomas, fi ve papillomas, two cases of stromal fibrosis, one case of pseudoangiomatous hyperplasia, one case of focal infl ammation, and nine areas of benign breast tissue.
Of patients with verifi ed cancer status, 143 were recalled for additional diagnostic studies because of abnormal fi ndings: Of 936 patients, 72 (8%) were recalled because of abnormal fi ndings with mammography only, 55 (6%) were recalled because of abnormal fi ndings with gamma imaging only, and 16 (2%) were recalled because of abnormal fi ndings with both modalities. The total recall rates for mammography and gamma cipants had atypical ductal hyperplasia detected with mammography only, and one participant had atypical ductal hyperplasia detected with gamma imaging only. One atypical papilloma was found with gamma imaging only. There were no upgrades to malignancy at excision.
Thirty-seven benign lesions in 35 patients were detected: fi ve with mammography only, 22 with gamma imaging only, six with both modalities, and four with either subsequent US or MR imaging. Three of the benign lesions did not warrant biopsy because of previous confi rmation at biopsy. The 28 falsepositive lesions detected with gamma mammography and gamma imaging combined was 91% (10 of 11), with P = .016 for the combination versus mammography alone. If we had defi ned a fi nding on the screening digital mammogram of BI-RADS category 3 as indicative of a positive result, the combined sensitivity of mammography and gamma imaging would be 100% (11 of 11), compared with the sensitivity of mammography alone, which was 36% (four of 11), with P = .016. Gamma imaging was more sensitive to invasive cancer than was mammography (seven of seven versus two of seven), with P = .063 ( Fig 4 ) .
Four of 936 (0%) patients were diagnosed with atypical lesions. Two parti- In one patient with two tumors, one was detected with gamma imaging only and one was detected with both mammography and gamma imaging. † Cancer was detected at 6-month follow-up diagnostic mammography performed 184 days following study entry.
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imaging were 9% (88 of 936) and 8% (71 of 936), respectively ( P = .218). PPV 1 for mammography and gamma imaging was 3% (three of 88) and 12% (nine of 73), respectively ( P = .01).
Of 88 patients recalled because of abnormal screening mammographic fi ndings, recommendations included diagnostic or extra mammographic views in 83, directed US in 50, MR imaging in fi ve, and biopsy in 17. Gamma imaging was positive in 73 patients, which triggered a combination read with screening mammography. Of these 73, in two, interpretation was resolved through review of the current screening mammogram, and in 71, patients were recalled for additional diagnostic evaluation, which included diagnostic or extra mammographic views in 66, directed US in 69, MR imaging in 13, biopsy in 36, and 6-month follow-up gamma imaging in 25 .
Biopsies were performed in 50 lesions in 45 patients, yielding 12 cancers, four atypical lesions, and 34 benign results. Nine biopsies in 1% (nine of 936) of patients were prompted by mammography only, resulting in one cancer, two atypical lesions, and six benign lesions. Twenty-eight biopsies in 3% (28 of 936) of patients were prompted by fi ndings with gamma imaging only, resulting in detection of eight cancers, two atypical lesions, and 18 benign lesions. Eight biopsies in 1% (eight of 936) of patients were prompted by both mammographic and gamma imaging fi ndings, resulting in detection of two cancers and six benign lesions. Five biopsies in 1% (fi ve of 936) of patients were prompted by other imaging or clinical fi ndings, resulting in detection of one cancer and four benign lesions.
Three of 17 (18%) biopsies prompted by mammographic fi ndings yielded a cancer diagnosis, and 10 of 36 (28%) biopsies prompted by gamma imaging fi ndings yielded a cancer diagnosis ( P = .36). The 17 mammographic fi ndingprompted biopsies were performed with either a stereotactic ( n = 9) or US-guided ( n = 8) core biopsy technique. The 36 gamma imaging fi nding-prompted biopsies were performed by using a stereotactic ( n = 1), US-guided ( n = 31), Table 4 Summary In patient 1, lesions a and b were both detected in the same breast.
||
Cancer was detected on the basis of fi ndings on the 6-month follow-up diagnostic mammogram obtained 184 days following study entry.
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Rhodes et al signifi cantly higher for gamma imaging compared with mammography (12% vs 3%, P = .01). Although the recall rates for mammography and gamma imaging did not differ significantly, there was a trend toward a lower recall rate for gamma imaging. Although fi ndings at gamma imaging prompted more biopsies than did those at mammography, the PPV of gamma imaging fi nding-prompted biopsies (PPV 3 ) was higher than was the PPV of mammographic finding-prompted biopsies, although this difference did not reach signifi cance. Dedicated dual-head gamma imaging compares very favorably with other modalities in the screening of women with dense breasts. In a subgroup analysis of the Digital Mammography Imaging Screening Trial, digital mammography demonstrated improved sensitivity to screen-fi lm mammography only in the subgroup of women younger than 50 years old who had dense breasts and who were of pre-or perimenopausal status; however, even in this subgroup, the sensitivity was below 60% ( 10,41 ).
Our study population was similar to that in the American College of Radiology Imaging Network National Breast Ultrasound Trial ( 13 ). Although we did not compare gamma imaging directly with US in our study, the sensitivity, PPV, and supplemental diagnostic yield reported in our study are higher than those reported for US.
The sensitivity of screening mammography is lower in our study compared with the sensitivity in the American College of Radiology Imaging Network National Breast Ultrasound Trial or to the Digital Mammography Imaging Screening Trial despite the fact that 73% of subjects in our study underwent digital mammography. However, the sensitivity of mammography in our study is comparable to the sensitivity of mammography in the prospective highrisk MR imaging screening trials ( 16 ) . In five of the six studies, the sensitivity of mammography was 40% or lower, whereas the sensitivity of screening MR imaging ranged from 77% to 94% ( 16, 42 ) . Note that table 2 in the Saslow et al study ( 16 ) erroneously reports a screening methods for breast cancer in women with dense breasts. Mammography and gamma imaging combined was signifi cantly more sensitive than was mammography alone in the detection of cancer (91% vs 27%, P = .016). The specifi city of gamma imaging and mammography was similar (93% and 91%, respectively), although the specifi city of gamma imaging and mammography combined was signifi cantly lower than that of mammography alone ( P , .001). Screening mammograms were read in the context of available clinical background and comparison with current and prior breast imaging studies, whereas this was a prevalent screening for gamma imaging, in which images were read without the benefi t of any other imaging or clinical information. As has been seen with mammography and MR imaging, the specifi city of gamma imaging would likely increase with annual incidence screening when results of prior studies would be available for review ( 40 ) .
The PPV of a screening examination with abnormal fi ndings (PPV 1 ) was or MR imaging-guided ( n = 3) core biopsy technique, and in one patient, an excisional biopsy was performed.
Of participants without cancer, 840 of 925 (specifi city, 91%) had true-negative fi ndings with mammography, and 861 of 925 (specifi city, 93%) had true-negative fi ndings with gamma imaging ( P = .069). The specifi city of mammography and gamma imaging combined was significantly less than that for mammography alone: With the combination of both tests, 788 participants had true-negative fi ndings ( P , .001).
When uptake categories of 1-5 were used, moderate agreement was observed between ( k = 0.52) and within ( k = 0.56) readers. Use of the three combined categories resulted in substantial agreement, with interreader agreement of k = 0.62 and intrareader agreement of k = 0.66.
Discussion
We compared mammography and dedicated dual-head gamma imaging as 
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Rhodes et al one-quarter of the participants had undergone screen-fi lm mammography. Of eight patients with cancers that were not detected with mammography, seven underwent digital mammography. Fourth, because inclusion in the study was based on the breast density on the past prior mammogram, 14% (134 of 936) of subjects in the analysis set had nondense breasts at the time the study mammogram was obtained. If inclusion of these subjects introduced any bias, it would likely be in favor of mammography, as the sensitivity of mammography is higher in nondense versus dense breasts ( 4-11 ). Finally, our follow-up was limited in 3% of cases to less than 1 year for imaging and relied on patient interview for verifi cation in 2% of cases. This could have decreased our false-negative rate. Gamma imaging has the capability to depict small, node-negative breast cancers that are not detected with mammography; however, we have not demonstrated that this capability translates into a mortality reduction, an end point that would require years and considerable resources to investigate. We have relied on the surrogate end point of tumor size. The median size of supplemental tumors detected by using gamma imaging only was 11 mm. Investigators in numerous studies have demonstrated that tumor size correlates with mortality, with size less than 20 mm conferring a survival advantage (49) (50) (51) . The association between lethality and tumor size is strongest in women with lymph node-negative cancer ( 52 ) . In this series, all cancers detected by using gamma imaging only were node-negative.
Although mammography added little increased diagnostic yield to gamma imaging in this study, we consider gamma imaging as an adjunct rather than as an alternative to screening mammography, given that mammography remains the only screening modality for which an associated reduction in breast cancer mortality has been demonstrated. In addition, we do not yet have suffi cient data to determine the sensitivity of gamma imaging for DCIS detection in a screening setting. Further studies are needed to see whether gamma imaging graphically occult cancer is substantial ( 32, 33 Tcsestamibi is approximately 6.5 mSv. By comparison, the radiation dose to the breast from a screening mammogram translates to an effective dose of 0.7-1.0 mSv. An advantage of dual-head CZT-based gamma imaging is the capability to improve technical aspects of the system to reduce administered radiation dose. Since the completion of the study, we optimized the gamma detector collimators, improved use of the CZT energy spectra, and introduced noise reduction algorithms that have allowed a reduction in the administered dose to approximately 148 MBq (4 mCi), yielding an effective dose of less than 1.3 mSv, which is comparable to that with screening mammography ( 47, 48 ) . While further study is needed to validate low-dose dedicated dual-head gamma imaging in a large screening study, this study demonstrates proof of principle of the effectiveness of gamma imaging in the screening setting.
Our study had several limitations. First, subjects were not randomized as to order of imaging studies. However, consents were obtained from all participants prior to imaging, and all images were interpreted by radiologists who were blinded to the results of the other imaging study, so it is unlikely that any bias was introduced. Second, the results may not be generalizable to women without the increased risk inclusion criterion or to other breast imaging centers. Third, because our institution was in the process of transitioning from screen-fi lm to digital mammography during the course of this trial, approximately sensitivity of 100% for MR imaging in the Sardanelli study ( 42 ) , which was listed as in press at the time the Saslow et al study was published, whereas the actual sensitivity from the published Sardanelli et al study is 94%. We hypothesize that the low sensitivity of mammography in our study and the MR imaging studies relates to the detection of small cancers by using gamma imaging and MR imaging that would have remained undetected by using digital mammography, whole-breast screening US, or clinical examination even at 1-year follow-up. Thus, these small cancers might not have been captured in sensitivity analyses of studies that relied on US and/or digital mammography as the reference standard for detection.
A current disadvantage of the technology evaluated in this study is the lack of direct biopsy capability. Of the 28 patients with lesions identifi ed with gamma imaging that were occult at screening mammography, most were localized at diagnostic mammography and/or US, but three required MR imaging for localization. Biopsy capabilities have been developed for breast-specifi c gamma imaging and are under development for the dedicated dual-head gamma camera used in this study.
In the American Cancer Society guidelines for breast screening with MR imaging as an adjunct to mammography, it was concluded that data were insuffi cient to recommend screening MR imaging in women with extremely dense breasts, although results of studies pertaining to the evaluation of MR imaging in women with breast cancer and mammographically dense breasts suggest that density does not affect sensitivity ( 16, (43) (44) (45) (46) . The results in our study and in other studies indicate that the sensitivity of gamma imaging is not reduced in women with dense breasts ( 17, 25, 30 ) . Dense parenchyma is the factor most closely associated with failure to detect breast cancer by using mammography ( 4 ) . Given that approximately one-half of women younger than the age of 50 years and one-third of women 50 years and older have mammographically dense breasts, the number of women at risk for mammo- could replace screening mammography in certain populations or whether the two modalities could be alternated synergistically.
The addition of dedicated dual-head gamma imaging to screening mammography yielded signifi cantly improved sensitivity while maintaining equivalent specificity in women with mammographically dense breasts. With the implementation of radiation dose reduction techniques, gamma imaging may offer an effective supplemental imaging technique to the subgroups of women in whom the sensitivity of mammography is limited.
